Literature DB >> 3411122

Dose-response studies of intracerebroventricular infusion of aldosterone in sensitized and non-sensitized rats.

E P Gomez Sanchez1.   

Abstract

We have shown previously that the intracerebroventricular (icvt) infusion of 5 ng/h aldosterone (ALD) in the sensitized rat (one kidney removed, 1% NaCl plus 0.15% KCl solution to drink) produced hypertension similar in amplitude and time of onset to a 100-fold dose administered subcutaneously (s.c.), while a 5-ng/h subcutaneous infusion had no effect on blood pressure (BP). Dose-response studies on the icvt infusion of ALD were carried out in sensitized and non-sensitized (intact, with tap water to drink) male Sprague-Dawley rats (SDR). In both studies, a control group received the diluent, artificial cerebrospinal fluid (CSF), icvt. In sensitized rats, the pressures became significantly (P less than 0.05) elevated at day 7 in those receiving 15 ng/h icvt, day 11 in those receiving 5 ng/h icvt and 500 ng/h s.c. and day 18 in those receiving 1.5 ng/h icvt. The indirect systolic BPs at day 20 of infusion were 119 +/- 0.8 (s.e.) mmHg for controls, 182 +/- 5 for 15 ng/h icvt, 140 +/- 2 mmHg for 5 ng/h icvt, 131 +/- 1 mmHg for 1.5 ng/h icvt, 125 +/- 1 mmHg for 0.5 ng/h, and 159 +/- 5 mmHg for 500 ng/h s.c. Recovery (removal of pumps and return to water to drink) for 18 days resulted in the return of normal pressures in all groups except the 15 ng/h, icvt group in which pressures remained slightly, but significantly elevated at 127 +/- 3 mmHg. In non-sensitized rats, the pressures became significantly elevated in animals receiving 45 ng/h icvt and 1 microgram/h s.c. by day 14.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411122     DOI: 10.1097/00004872-198806000-00002

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

Review 1.  Role of central mineralocorticoid receptors in cardiovascular disease.

Authors:  C E Gomez-Sanchez; E P Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Central regulation of blood pressure by the mineralocorticoid receptor.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 5.  Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?

Authors:  Elise P Gomez-Sanchez
Journal:  Trends Endocrinol Metab       Date:  2011-03-21       Impact factor: 12.015

Review 6.  Role of mineralocorticoid action in the brain in salt-sensitive hypertension.

Authors:  Kenji Oki; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-01       Impact factor: 2.557

7.  Aldosterone and Salt Loading Independently Exacerbate the Exercise Pressor Reflex in Rats.

Authors:  Masaki Mizuno; Ryan M Downey; Jere H Mitchell; Richard J Auchus; Scott A Smith; Wanpen Vongpatanasin
Journal:  Hypertension       Date:  2015-07-20       Impact factor: 10.190

Review 8.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

9.  Conditional Deletion of Hsd11b2 in the Brain Causes Salt Appetite and Hypertension.

Authors:  Louise C Evans; Jessica R Ivy; Caitlin Wyrwoll; Julie A McNairn; Robert I Menzies; Thorbjørn H Christensen; Emad A S Al-Dujaili; Christopher J Kenyon; John J Mullins; Jonathan R Seckl; Megan C Holmes; Matthew A Bailey
Journal:  Circulation       Date:  2016-03-07       Impact factor: 29.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.